Screening for Cognitive Impairment in Multiple Sclerosis with MOCA Test

OBJECTIVE: Cognitive dysfunction is currently recognized as a significant cause of disability in multiple sclerosis (MS). The Montreal Cognitive Assessment (MOCA) is screening device used to evaluate executive functions, visuo-spatial abilities, language, attention, and concentration, abstract thinking, memory, and orientation domain. The aim of this study is to compare cognitive functions of MS patients with age-matched controls using MOCA test. METHODS: Thirty nine subjects with a diagnosis of relapsing-remitting MS according to the 2010 revised McDonald criteria and 20 healthy volunteer controls participated in this study. Patients and controls underwent Turkish version of MOCA test. Total and subgroup scores were compared. RESULTS: Total MOCA score in MS patients and controls were 21,74±4,48 and 26,9±2,53 respectively. Total MOCA score of MS patients was significantly lower than controls. Significant deterioration was also found in language, attention, memory and executive functions domain. Disease duration and expanded disability status scale (EDSS) did not differ in patients with and without cognitive deficits. CONCLUSION: Patients with MS showed deterioration in language, attention, working and long term-memory and executive functions compared to controls. MOCA is a simple, stand-alone cognitive screening test with superior sensitivity. Our findings suggest that the MOCA test may be useful for screening cognitive impairment in MS patients early in the disease course